Pfizer has filed a lawsuit against Novo Nordisk and Metsera in an attempt to force through its takeover of the weight-loss drug developer and prevent Novo Nordisk from taking its rival bid forward.

Novartis' third-quarter results have exemplified the reason for its recent deal-making activity, as heart failure therapy Entresto finally succumbed to the entry of ...

MSD and Eisai's combination of Keytruda and Lenvima has become a driver of growth for both products, but their efforts to extend the regimen into liver cancer have hit a hurdle. The two partners said ...

CSL has said that with flu jab rates in the US down between 12% and 14% this year, it has decided to delay the planned spinout of its Seqirus vaccines business and cut its profit forecast for the ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a deal that could be worth up to £268 million ($358 million). The object of ...

So it was that pharmaphorum sat down with Jan Kirsten, global head of the rare tumour business for SpringWorks Therapeutics – a healthcare company of Merck KGaA – to discuss mirdametinib’s application ...

Faced with soaring demand for leucovorin for use in children with autism, the American Academy of Paediatrics (AAP) has said ...

Final draft guidance on NHS use of the drug marks a "significant shift" from NICE's 2021 decision on the drug as a first-line ...

As drug development becomes more complex, so do the demands for accurate, reproducible bioanalytical data to prove their ...

AZ is already a major presence in gMG treatment with its current antibody-based anti-C5 drugs – Soliris (eculizumab) and Ultomiris (ravulizumab) – which are dosed by intravenous infusion every two and ...

As clinical momentum grows for novel DDR targets such as ATR, CHK1/2, WEE1, and DNA-PK, this forum delivers a front-row seat ...

Returning as Europe’s longest-standing and definitive ADC forum, the 16th World ADC London is the week for anyone working in ...